Clinical trials: Axillary Hyperhidrosis
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Hyperhidrosis
Study of Glycopyrronium in Axillary Hyperhydrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530281
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 31 sites in United States, Germany
- Volunteers
- 344 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects.
- Trial name
- NCT02193139
- Testing
- WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- Watson Pharmaceuticals
Hyperhidrosis
Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
The purpose of the study is to assess the safety of 2 doses of glycopyrrolate compared to 2 doses of glycopyrronium and vehicle (5 treatment arms) for the treatment of axillary hyperhidrosis when applied once daily for 4 weeks…
- Trial name
- NCT02129660
- Testing
- Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD
- Where
- 15 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Journey Medical Corporation
Axillary Hyperhidrosis
Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis
To evaluate the Ulthera System and the 7-3.0mm transducer for treating axillary hyperhidrosis.
- Trial name
- ULT-218 (NCT03320096)
- Testing
- Microfocused ultrasound with visualization
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis Primary Focal Axilla
Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency
The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF.
- Trial name
- NCT05860972
- Testing
- Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.
- Where
- 4 sites in United States, Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
Hyperhidrosis
GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
The primary objective of this study is to demonstrate superiority of single treatment of GSK1358820 (hereinafter, referred to as BOTOX®) over placebo in terms of the efficacy of treatment with BOTOX® 50 U in each axilla (100 U in…
- Trial name
- NCT01128738
- Testing
- GSK1358820
- Where
- 14 sites in Japan
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis
A study using Botulinum Toxin Type A in adolescents with axillary hyperhidrosis.
- Trial name
- NCT00168415
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 144 people
- Sponsor
- Allergan
Primary Focal Hyperhidrosis, Axilla
Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis
This is a prospective, multi-center, parallel, randomized, blinded study. The study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the DTS-G2…
- Trial name
- DRI-UP (NCT00931359)
- Testing
- DTS-G2 System
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Miramar Labs
Axillary Hyperhidrosis
Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis
The purpose of this study is to determine whether treatment by the miraDry System can safely reduce the severity of axillary hyperhidrosis (excessive underarm sweating).
- Trial name
- NCT01091129
- Testing
- miraDry System (treatment with energy)
- Where
- 2 sites in Canada
- Volunteers
- 31 people
- Sponsor
- Miramar Labs
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
- Trial name
- NCT02100072
- Testing
- Nd:YAG 1440 nm laser
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cynosure, Inc.
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
This is a three-year study in subjects with axillary hyperhidrosis involving injection of Botulinum Toxin Type A into the axilla to reduce sweating.
- Trial name
- NCT00168402
- Testing
- Botulinum Toxin Type A
- Volunteers
- 193 people
- Sponsor
- Allergan
Hyperhidrosis
Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
Up to 60 subjects will be enrolled into one of five treatment groups. Subjects enrolled in Groups A, B or C will undergo axillary punch biopsies during the course of the trial to determine the number and depth of the sweat…
- Trial name
- NCT01708551
- Testing
- Ulthera System Treatment
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham…
- Trial name
- NCT01722461
- Testing
- Ulthera System
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ulthera, Inc
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.
- Trial name
- NCT05863104
- Testing
- Glycopyrronium Bromide (GPB) Cream
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
The Purpose of the study is to evaluate the 1440nm Laser Assisted Selective Photothermolysis vs. Botulinum Toxin or miraDry® Microwave Thermolysis For Treatment of Axillary Hyperhidrosis.
- Trial name
- NCT01811004
- Testing
- miraDry, Nd:YAG Laser, Botox®
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cynosure, Inc.